Dingdang Health Technology Group Ltd. executed an on-market buyback of 155,000 ordinary shares on 6 October 2026, paying between HKD 0.83 and HKD 0.84 per share for a total consideration of approximately HKD 0.13 million. The volume-weighted average price was about HKD 0.84 per share.
Post-transaction, the company’s issued share capital (excluding treasury shares) declined to 1.23 billion shares, a reduction of 0.01%. Concurrently, treasury share holdings increased from 6.00 million to 6.16 million, while the total issued share count remained unchanged at 1.24 billion shares.
The repurchase forms part of the mandate granted by shareholders on 23 June 2026, which authorises the company to buy back up to 124.32 million shares. Including the latest purchase, Dingdang Health has repurchased 9.02 million shares under this mandate, equating to 0.73% of the company’s outstanding shares on the mandate date, leaving roughly 115.30 million shares—over 92% of the authorised limit—still available for potential future buybacks.
Under Hong Kong listing rules, the company is restricted from issuing, selling or transferring any shares, including treasury shares, for 30 days following the latest repurchase, setting a moratorium until 5 November 2026.
Comments